To include your compound in the COVID-19 Resource Center, submit it here.
An ongoing, dose-escalation, open-label, U.S. Phase I trial in 23 patients with refractory solid tumors showed that
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury